TrialsgrambêtaRCTs are beautiful
ESC Congress 2026Présenté sam. 29 août · 11:00 UTC+2Hot Line 3Tous les essais Hot Line →

LIBREXIA ACS

2026

A Phase 3, Randomized, Double-blind, Placebo-controlled, Event-driven Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, After a Recent Acute Coronary Syndrome (Librexia ACS)

In 14,194 patients with a recent acute coronary syndrome, milvexian added to antiplatelet therapy did not reduce cardiovascular death, myocardial infarction or ischaemic stroke compared with placebo.

Résultat

Efficacité: Time to first occurrence of the composite of cardiovascular death, myocardial infarction or ischaemic strokeHR 1,05 (IC à 95 % 0,91-1,21) · P = 0,50

Sécurité: Intracranial or fatal bleedingHR 1,04 (IC à 95 % 0,58-1,87) · P = 0,88

En dessous de 1 en faveur de milvexian added to antiplatelet therapy, au-dessus de 1 en faveur de placebo.

Taux d’événements Milvexian added to antiplatelet therapy 5,4% vs placebo 5,1% (time to first occurrence of the composite of cardiovascular death, myocardial infarction or ischaemic stroke)

Également rapporté: Cardiovascular death, myocardial infarction or ischaemic stroke . Stopped for futility at the interim analysis in November 2025.

Publication originale
Sous-thème
Factor XIa inhibition
Schéma
International, multicentre, randomised, double-blind (quadruple-masked), placebo-controlled, event-driven phase 3 trial; 1:1 allocation to milvexian or matched placebo on top of investigator-chosen standard antiplatelet therapy (SAPT or DAPT); randomisation stratified by planned type and duration of antiplatelet therapy; follow-up planned until 875 primary-endpoint events (up to about 3.5 years)
Pertinence
Important: l’un des piliers parmi d’autres.
Source
Gibson CM, Steg PG, Bahit MC, et al. N Engl J Med. 2026; published online 29 August.doi 10.1056/nejmoa2608717

Discussion et critique

Factor XI inhibition promised the separation every antithrombotic programme is chasing: fewer events without more bleeding. In 14,194 patients after an acute coronary syndrome, milvexian delivered the second half and none of the first: identical bleeding, identical events, stopped for futility. The bleeding safety is real and matters for the atrial fibrillation and stroke programmes still running, but on top of modern antiplatelet therapy after ACS there was nothing left to prevent.

Discuté dans des podcasts